<p>To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of the voluntary scheme for branded medicines pricing and access on (a) development of and (b) access to (i) Graft-versus-Host disease therapies, (ii) CAR-T therapies and (iii) other innovative therapies for rare conditions.</p>